We studied 15 children with complex partial seizures in whom one or more seizure type was exacerbated during treatment with carbamazepine. The most common seizure type that was exacerbated was generalized atypical absence (11 patients). Four patients had more frequent and severe generalized convulsive seizures. Monitoring with video-electroencephalographic telemetry suggested that the electroencephalogram can be used to predict the risk of seizure exacerbation with carbamazepine. A bilaterally synchronous spike-and-wave discharge of 2.5 to 3 cycles per second is predictive of increased atypical absence seizures with carbamazepine, whereas generalized bursts of spikes and slow waves of 1 to 2 cycles per second suggest a risk of increased generalized convulsive seizures. Carbamazepine should be used with caution in children with a mixed seizure disorder, particularly those with a generalized bilaterally synchronous discharge of 2.5 to 3 cycles per second on the electroencephalogram. The drug should be considered a possible precipitating factor in any child with an increased frequency of generalized convulsive or generalized absence seizures concomitant with administration of this anticonvulsant agent.
This article has been cited by other articles:
Trevathan, E., Kerls, S. P., Hammer, A. E., Vuong, A., Messenheimer, J. A.
(2006). Lamotrigine Adjunctive Therapy Among Children and Adolescents With Primary Generalized Tonic-Clonic Seizures. Pediatrics
118: e371-e378
[Abstract][Full Text]
Thomas, P., Valton, L., Genton, P.
(2006). Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain
129: 1281-1292
[Abstract][Full Text]
Marini, C., Parmeggiani, L., Masi, G., D'Arcangelo, G., Guerrini, R.
(2005). Nonconvulsive Status Epilepticus Precipitated by Carbamazepine Presenting as Dissociative and Affective Disorders in Adolescents. J Child Neurol
20: 693-696
[Abstract]
Lhatoo, S D, Sander, J W A S, Shorvon, S D
(2001). The dynamics of drug treatment in epilepsy: an observational study in an unselected population based cohort with newly diagnosed epilepsy followed up prospectively over 11-14 years. J. Neurol. Neurosurg. Psychiatry
71: 632-637
[Abstract][Full Text]
Tatum, W. O. IV, Galvez, R., Benbadis, S., Carrazana, E.
(2000). New Antiepileptic Drugs: Into the New Millennium. Arch Fam Med
9: 1135-1141
[Abstract][Full Text]
Chadwick, D.
(1999). Does withdrawal of different antiepileptic drugs have different effects on seizure recurrence?: Further results from the MRC Antiepileptic Drug Withdrawal Study. Brain
122: 441-448
[Abstract][Full Text]
Webb, D. W, Coleman, H., Fielder, A., Kennedy, C. R
(1998). An audit of paediatric epilepsy care. Arch. Dis. Child.
79: 145-148
[Abstract][Full Text]
Lortie, A., Chiron, C., Dumas, C., Mumford, J. P., Dulac, O.
(1997). Optimizing the Indication of Vigabatrin in Children With Refractory Epilepsy. J Child Neurol
12: 253-259
[Abstract]
Stafstrom, C. E., Nohria, V., Loganbill, H., Nahouraii, R., Boustany, R.-M., DeLong, G. R.
(1995). Erythromycin-Induced Carbamazepine Toxicity: A Continuing Problem. Arch Pediatr Adolesc Med
149: 99-101
[Abstract]
Dodson, W. E., Bourgeois, B. F.D.
(1994). Pharmacology and Therapeutic Aspects of Antiepileptic Drugs in Pediatrics. J Child Neurol
9: 281-287
[Abstract]
Howard, R.S., Trend, P. StJ., Townsend, H.R.A.
(1990). EEG Appearances in Acute Carbamazepine Toxicity. Hum Exp Toxicol
9: 313-315
[Abstract]
Previous
